A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Cabergoline

Ergot Derivative class · 5 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval2007-03-07
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$10.1M in CY2024 Part D spend138K claims · 41K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.41/unit
7 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.41
Across all dosage forms in distribution.
Highest NADAC
$1.41
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Cabergoline used for?

Cabergoline is a Ergot Derivative medication tracked in Medicare Part D.

Is there a generic for Cabergoline?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Cabergoline?

Across 329 Part D plans, Cabergoline averages $1.41/unit (NADAC). Lowest available: $1.41/unit. Highest in distribution: $1.41/unit.

Is Cabergoline on the FDA shortage list?

No. Cabergoline is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Ergot Derivative2 alternatives in D1
01
Bromocriptine
Brand: CYCLOSET
$1.65Lowest NADAC
4Generic mfrs
$12.5MCY24 Part D spend
Compare →
02
Methylergonovine
Brand: Methergine
$5.66Lowest NADAC
8Generic mfrs
$503,249CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (5 approvals on file) · NADAC unit costs: CMS NADAC weekly file (7 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.